News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search

 

Cataract treatment in the blink of an eye

4 May 2005

Cataract treatment in the blink of an eye

Researchers at the University of Canterbury are pioneering the development of an eye drop to halt the development of cataracts.

Cataracts are the major cause of blindness worldwide. Until now, the only option has been corrective surgery.

However, researchers from the University’s Chemistry Department are trying to identify a compound which would act as an inhibitor and prevent cataracts from developing.

Cataracts cause the lens of the eye to become cloudy and prevent the passage of light.

Scientists believe that an increase in activity of the protein-destroying calpain enzyme causes the breakdown of the major lens proteins, the crystallins, leading to opaque lenses.

The Canterbury team, led by Professor Andrew Abell and Professor Jim Coxon, believe the inhibition of calpain activity could halt cataract formation.

“It is our goal to develop a compound to treat cataracts that can be incorporated into an eye drop and prescribed to treat cataracts,” Professor Abell says.

The UC researchers have been working closely with colleagues at Lincoln University who have developed an animal model to allow a study of the progression of cataracts.
The Lincoln study has focused on a flock of sheep genetically predisposed to cataracts.

A calpain inhibitor has been tested on the animals. It was applied as eye drops and slowed, but did not prevent, the development of cataracts.

“These results are promising as they support our hypothesis that calpain activity is important in the development of the cataract and showed that inhibitors could interfere with cataract progression,” Professor Abell says.

“Long waiting lists exist for cataract surgery in most affluent countries and one of our goals is to improve the quality of life of those that currently face blindness while awaiting a cataract operation. This is of even greater importance to third world countries.”

The Canterbury team is working with Douglas Pharmaceuticals (NZ) to develop more efficient eye delivery systems and has links with Senju, a Japanese pharmaceutical company which specialises in eye care products.

ENDS


© Scoop Media

 
 
 
Culture Headlines | Health Headlines | Education Headlines

 
At Bats: Locke - The World Theatrical Premiere

On the eve of the biggest challenge of his career, Ivan Locke receives a phone call that sets in motion a series of events that will unravel his family, job and soul... More>>

Other Elections: Kea Crowned Bird Of The Year

These large, green mountain parrots are known for their curiosity and intelligence. Once numbering in the hundreds of thousands, they are now classified as Nationally Endangered with just 3,000 - 7,000 birds remaining. More>>

ALSO:

Howard Davis Review: Conflict & Resistance - Ria Hall's Rules of Engagement

From the aftermath of war through colonisation to her own personal convictions, Hall's new CD addresses current issues and social problems on multiple levels, confirming her position as a polemical and preeminent voice on the indigenous NZ music scene. More>>

Howard Davis Review: Another Time, Another Place - David Friesen Trio Live

"It has been said of David Friesen that he does for the art of bass playing what Pythagoras did for the triangle" - Patrick Hinley, Jazz Times. At Wellington's newest jazz venue, the cozy and intimate Pyramid Cub, the trio clicked together from the opening bars, presenting many of the tunes from their marvelous new recording. More>>

Howard Davis Review: The Father - Descending Into The Depths of Dementia

Florian Zeller's dazzling drama The Father explores the effects of a deeply unsettling illness that affects 62,000 Kiwis, a number expected to grow to 102,000 by 2030. More>>

 
 
 
 
 

LATEST HEADLINES

  • CULTURE
  • HEALTH
  • EDUCATION